Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 52-Week High – What’s Next?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $834.22 and last traded at $840.4730, with a volume of 94615 shares trading hands. The stock had previously closed at $810.24.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Finally, Leerink Partners upped their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $801.70.

Regeneron Pharmaceuticals Stock Up 3.5%

The stock has a fifty day moving average price of $683.57 and a 200-day moving average price of $714.66. The firm has a market cap of $86.38 billion, a PE ratio of 20.71, a PEG ratio of 1.37 and a beta of 0.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $12.81 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,400 shares of company stock worth $1,090,030. Corporate insiders own 6.97% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in REGN. Brighton Jones LLC raised its stake in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 686 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $226,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $3,183,000. Gabelli Funds LLC raised its position in shares of Regeneron Pharmaceuticals by 3.0% during the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after purchasing an additional 55 shares during the period. Finally, Sei Investments Co. raised its position in shares of Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after purchasing an additional 5,120 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.